Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Anxiety in men undergoing active surveillance for prostate cancer tapers over time

03 Dec 2018
Blue prostate cancer awareness ribbon

Men undergoing active surveillance for prostate cancer exhibit moderate risk of cancer-specific mortality, which significantly declines over time, a recent study reports.

Researchers used a modified version of the Memorial Anxiety Scale for Prostate Cancer to evaluate cancer-specific anxiety in 413 men (median age 61 years) undergoing active surveillance at a single tertiary care centre. Median prostate-specific antigen at baseline was 4.4 ng/mL.

Participants completed a median of two surveys each. The time from surveillance initiation to the first and last survey was 2.8 and 3.7 years, respectively. Majority of participants had grade 1 disease at the beginning of surveillance.

During the first year of surveillance, an estimated 29 percent of the men were at risk of prostate cancer-related anxiety. This declined to 14 percent after 7.5 years, the rate of which reached significance (odds ratio [OR], 0.87 per year; 95 percent CI, 0.79–0.95; p=0.003).

“There was a possible explanation of these findings. If anxious patients gradually quit active surveillance due to anxiety, anxiety levels would appear to fall with an increasing duration of time on surveillance,” researchers offered.

However, upon analysis of the reasons for discontinuation, they found that only 2–3 percent of the total cohort switched to treatment for personal reasons. This therefore did not account for the 15-percent absolute decrease in the risk of anxiety over time.

Multivariable generalized estimating equation models adjusted for active surveillance time showed that men who reported a better overall state of health were significantly less likely to be at risk of anxiety (OR, 0.83; 0.74–0.93; p=0.001).

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.